Scarica l'app Stockscreener
0.4357
10.46%
-0.0509
Dopo l'orario di chiusura:
.42
-0.0157
-3.60%
Precedente Chiudi:
$0.4866
Aprire:
$0.48
Volume 24 ore:
404.06K
Relative Volume:
0.66
Capitalizzazione di mercato:
$4.76M
Reddito:
-
Utile/perdita netta:
$-16.73M
Rapporto P/E:
-0.0286
EPS:
-15.2598
Flusso di cassa netto:
$-14.29M
1 W Prestazione:
-34.50%
1M Prestazione:
-47.52%
6M Prestazione:
-82.07%
1 anno Prestazione:
-97.17%
Intervallo 1D:
$0.4357
$0.4801
Intervallo di 1 settimana:
$0.4357
$0.696
Portata 52W:
$0.4357
$55.00
Genprex Inc Stock (GNPX) Company Profile
Nome
Genprex Inc
Settore
Industria
Telefono
512-537-7997
Indirizzo
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.4357 | 5.32M | 0 | -16.73M | -14.29M | -15.26 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-26 | Iniziato | National Securities | Buy |
| 2019-04-29 | Iniziato | Noble Capital Markets | Outperform |
Genprex Inc Borsa (GNPX) Ultime notizie
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GNPX Q1 2026 Earnings: Continued Losses as Clinical-Stage Biotech Focuses on Pipeline ProgressEarnings Miss Streak - newsline.com
Genprex, Inc. Files Form 8-K With Nasdaq Listing and Company Information – June 2026 - Minichart
Genprex faces potential delisting from Nasdaq after bid price rule violation - Investing.com UK
Genprex Faces Nasdaq Delisting Notice, Plans Compliance Steps - TipRanks
Genprex Received Notice of Delisting - TradingView
Genprex (NASDAQ: GNPX) confronts Nasdaq delisting risk after sub-$1 bid price - Stock Titan
Genprex Inc. (GNPX) Edges Higher Amid Low-Volume Consolidation Near Key Support LevelsMid Cap Momentum - newsline.com
GNPX Should I Buy - Intellectia AI
Genprex Inc. (GNPX) Edges Higher on Modest Volume, Faces Key Resistance at $0.68MA Cross Alert - newsline.com
Genprex Q1 2026 Earnings: Net Loss of $0.64 Per Share as Clinical-Stage Operations ContinueEarnings Surprise Report - newsline.com
Genprex (GNPX) files shelf registration to sell up to $250M in securities - Stock Titan
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
GNPX Q1 2026 Earnings: Net Loss Widens as Clinical-Stage Biotech Advances PipelineCash Flow Report - newsline.com
Genprex trades under $1 as ASCO results land - Bez Kabli
Genprex (GNPX) Edges Lower Toward $0.75 Support as Biotech Sentiment WaversETF NAV Deviation - thelegaladvocate.com
Genprex (GNPX) Slips 1.86% as Stock Tests Key Support at $0.74Supply Zone - newsline.com
Genprex (GNPX) Q1 2026 Earnings: Continued R&D Investment as Gene Therapy Pipeline ProgressesRevenue Surprise History - The Legal Advocate
Genprex reports biomarker data from lung cancer gene therapy study - Investing.com UK
Genprex, Inc. Announces Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - marketscreener.com
Genprex reports biomarker data from lung cancer gene therapy study By Investing.com - Investing.com Nigeria
Genprex Highlights Biomarker Data for Reqorsa Lung Cancer Therapy - TipRanks
Biomarker data link Trop-2 to PFS in Genprex (NASDAQ: GNPX) trials - Stock Titan
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - PR Newswire
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Reports Net Loss with No Revenue; Stock Moves Up $0.74Operating Income Trends - The Legal Advocate
Genprex Inc. (GNPX) Edges Higher Amid Biotech Sector Cautious ToneLow Vol Factor - Newser
Genprex (GNPX) Q1 2026 Earnings Stay the Course — EPS $-0.64Expert Stock Picks - Newser
Why Is Genprex, Inc. (GNPX) Stock Down Today? - Meyka
Genprex (GNPX) Showcases Promising Diabetes Gene Therapy Results - GuruFocus
Genprex, Inc. Files Form 8-K With SEC – Company Information and Filing Details for May 14, 2026 - Minichart
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex Presents Positive Preclinical Data on Novel Gene Therapy for Type 2 Diabetes at ASGCT 2026 Meeting - geneonline.com
Genprex collaborators present diabetes gene therapy data By Investing.com - Investing.com India
Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT - TradingView
Genprex collaborators present diabetes gene therapy data - Investing.com
[8-K] Genprex, Inc. Reports Material Event - Stock Titan
Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Genprex (NASDAQ: GNPX) raises cash through share sales amid going concern risk - Stock Titan
Genprex (GNPX) warrant holders report 249,788 shares, 2.69% stake - Stock Titan
GNPX Genprex quarterly results lack key metrics as clinical programs advance, investors await pipeline update.Guidance Upgrade Report - newsline.com
Number of shareholders of Genprex Inc – LSE:0A8I - TradingView
GNPX (Genprex) Q1 loss narrower than expected, beating estimates by 37.8% despite zero revenue and shares ticking higher.Miss Estimates - newser.com
Top 3 Health Care Stocks That Are Set To Fly In Q2 - Benzinga
What Genprex (GNPX) is doing that changes everything (Momentum Building) 2026-05-06Standard Deviation - newsline.com
GNPX Forecast, Price Target & Analyst Ratings | GENPREX INC (NASDAQ:GNPX) - ChartMill
MSN Money - MSN
Genprex, Inc. Files Form 8-K With SEC: Company Information, Nasdaq Listing, and Regulatory Details - Minichart
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatm - GuruFocus
Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel - TipRanks
Genprex Inc Azioni (GNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Genprex Inc Azioni (GNPX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LONGNECKER BRENT M | Director |
Apr 14 '26 |
Sale |
1.23 |
8 |
10 |
9,157 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):